| 23rd week of 2016 patent applcation highlights part 9 |
| Patent application number | Title | Published |
|---|
| 20160158215 | TRANSORAL DOSAGE FORMS COMPRISING SUFENTANIL AND NALOXONE - The invention pertains to methods that include administering to a subject a transoral dosage form comprising a pharmaceutical carrier and sufentanil, and maintaining a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test. Related dosage forms are also disclosed. Also disclosed are transoral dosage forms and related methods, wherein a transoral dosage form may comprise: (1) about 5 to about 1000 micrograms of sufentanil; (2) about 50 micrograms to about 100 milligrams of naloxone; and (3) acidifying material in an amount sufficient to provide a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test; wherein the dosing period begins no earlier than about 1 minute after administration of the transoral dosage form, and ends no later than about 120 minutes after administration of the transoral dosage form. | 2016-06-09 |
| 20160158216 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF - The subject invention provides a mixture of crystalline laquinimod sodium particles, wherein (i) 90% or more of the total amount by volume of the laquinimod sodium particles have a size of 40 microns or less or (ii) 50% or more of the total amount by volume of the laquinimod sodium particle have a size of 15 microns or less, and wherein:
| 2016-06-09 |
| 20160158217 | Quinoline Carboxamide and Quinoline Carbonitrile Derivatives as mGluR2-Negative Allosteric Modulators, Compositions, and Their Use - The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) | 2016-06-09 |
| 20160158218 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein. | 2016-06-09 |
| 20160158219 | USE OF AN H4 AGONIST MOLECULE TO TREAT ACUTE LEUKEMIA - The present invention relates to the use of new chemical substances, the levogyre and dextrogyre enantiomers of (AMINO-7 TRIETHOXY-4, 5, 6 OXO-1 DIHYDRO-1, 3 ISOBENZOFURANNYL-3)-1 METHOXY-8 METHYL-2METHYLENEDIOXY-6, 7 TETRAHYDRO-, 2, 3, 4 ISOQUINOLEINE or tritoqualine, to treat acute myeloid or lymphoid leukemia, with the exception of type B leukemia. | 2016-06-09 |
| 20160158220 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 - The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof. | 2016-06-09 |
| 20160158221 | SUSTAINED RELEASE FORMULATION OF NALTREXONE - A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition. | 2016-06-09 |
| 20160158223 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 2016-06-09 |
| 20160158224 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 2016-06-09 |
| 20160158226 | ANTITUBERCULAR COMPOSITION COMPRISING RIFAMPICIN, ISONIAZID, ETHAMBUTOL AND PYRAZINAMIDE AND ITS PROCESS OF PREPARATION - The present invention relates to a monolayer tablet for use in the treatment of tuberculosis comprising a mixture of: granules comprising isoniazid, pyrazinamide, ethambutol or a pharmaceutically acceptable salt thereof and at least one granulation binder, rifampicin in powder form, extragranular excipients, wherein all of the granules have a particle size that is less than 0.599 mm, preferably less than 0.5 mm, more preferably less than 0.422 mm, and to its process of preparation. | 2016-06-09 |
| 20160158228 | SUSTAINED-RELEASE FORMULATION FOR INJECTION - The present invention relates to a composition comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof. In detail, the composition relates to a sustained release formulation for injection which maintains an effective blood level of the above-mentioned compound. | 2016-06-09 |
| 20160158229 | Mixtures of Heteropolycycles - A mixture of heteropolycycles has preferably two particular heteropolycycles and more preferably, no more than 10 wt. %, 5 wt. %, 2.5 wt. %, 1 wt. %, 0.5 wt. %, 0.1 wt. %, 0.01 wt. %, 0.001 wt. %, or no more than a detectable amount of one of the two. | 2016-06-09 |
| 20160158230 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER - Provided are compounds of formula (I), wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl; one of X, Y and W is CH and the two others are N; and Z is H or —C(R1)(R2)(R3). The compounds are inhibitors of isocitrate dehydronenase 2 (IDH2) mutants useful for treating cancer. | 2016-06-09 |
| 20160158231 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS FOR TREATING PERIPHERAL NEUROPATHY - The invention relates to HDAC inhibitors for the treatment of peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor. | 2016-06-09 |
| 20160158232 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND BENDAMUSTINE - The invention relates to pharmaceutical combinations comprising an HDAC inhibitor and bendamustine; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions for treating lymphoma in a subject in need thereof. | 2016-06-09 |
| 20160158233 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS - The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors (PDE5i) in combination with a) treatments, leading to increased cGMP mobilization, and/or b) tretaments correcting and/or potentiatiating CFTR function, and/or c) treatments currently used as standard of care in Cystic Fibrosis, and/or d) antinflammatory treatments for the preparation of medicaments for the treatment of Cystic Fibrosis (CF) with improved efficacy over methods of treatments already known. | 2016-06-09 |
| 20160158234 | BIHETEROARYL COMPOUNDS AND USES THEREOF - The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R | 2016-06-09 |
| 20160158235 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS - The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by EGFR kinase inhibitors are also provided. | 2016-06-09 |
| 20160158236 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID - The present patent application relates to a pharmaceutical composition comprising a transient receptor potential ankyrin-1 receptor (“TRPA1”) antagonist and a glucocorticoid. | 2016-06-09 |
| 20160158237 | Methods and Compositions for Treating Thyroid-Related Medical Conditions with Reduced Folates - The present invention provides methods and compositions for treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Additionally, it is commonplace to treat many thyroid conditions with anti-thyroid drugs or thyroid stimulating drugs. This practice alone is also responsible for causing, or not beneficially addressing, adverse conditions that can be prevented or treated through the methods and compositions discussed herein. | 2016-06-09 |
| 20160158238 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof - The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents. | 2016-06-09 |
| 20160158239 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS - Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein. | 2016-06-09 |
| 20160158240 | Compositions Containing Defined Caffeine and Theobromine Levels with Enhanced Cognitive Properties - The invention includes compositions and methods for improving cognitive function or reducing the anxiety effects of caffeine cravings. Caffeine and theobromine are naturally occurring and are both present in cocoa-derived food products or ingredients. The main substances used in the methods and food products of the invention comprise compounds known to influence the brain—caffeine and theobromine. When present in defined levels per serving, the caffeine and theobromine containing compositions of the invention result in surprising characteristics that can reduce the reliance on caffeine for habitual users, improve blood flow in the brain, and improve cognitive function. | 2016-06-09 |
| 20160158241 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER - Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer. | 2016-06-09 |
| 20160158242 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins - The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed. | 2016-06-09 |
| 20160158243 | IGF-1R SIGNALING PATHWAY INHIBITORS USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention provides compounds acting as Insulin/IGF signaling modulators useful in the treatment of neurodegenerative diseases and disorders. The invention provides pharmaceutical compositions including such compounds, and methods of using these compounds and compositions for the treatment of neurodegenerative diseases, in particular neurodegenerative diseases caused by proteotoxicity such as Alzheimer's disease. | 2016-06-09 |
| 20160158244 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS - This invention provides novel pharmaceutical compositions of the compound of formula (I): | 2016-06-09 |
| 20160158245 | PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS - A method of treating lymphoblastic leukemia, acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia or CD34 positive acute myeloid leukemia comprising the step of administering to a patient a pharmaceutically acceptable amount of a composition comprising a thienotriazolodiazepine compound according to Formula (1) as a solid dispersion wherein X is a halogen, R | 2016-06-09 |
| 20160158246 | METHOD OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) USING A BET-BROMODOMAIN INHIBITOR - A method of treating diffuse large B-cell lymphoma comprising administering to a patient a pharmaceutically acceptable amount of a composition comprising a thienotriazolodiazepine compound, said thienotriazolodiazepine compound being represented by Formula (I), wherein R | 2016-06-09 |
| 20160158247 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors - This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents. | 2016-06-09 |
| 20160158248 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT - The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal. | 2016-06-09 |
| 20160158249 | OCULAR THERAPY USING GLUCOCORTICOID DERIVATIVES SELECTIVELY PENETRATING POSTERIOR SEGMENT TISSUES - Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described. | 2016-06-09 |
| 20160158250 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES - The invention provides a method of treating a disease or condition mediated by vascular hyperpermeability in an animal. The method comprises administering an amount of a danazol compound effective to inhibit vascular hyperpermeability and an amount of a second drug effective to treat the disease or condition. The invention further provides a method of inhibiting vascular hyperpermeability when it is a side effect caused by administration of a drug to, or another treatment of, an animal. The method comprises administration of an amount of a danazol compound effective to inhibit the vascular hyperpermeability. The invention also provides a method of modulating the cytoskeleton of endothelial cells in an animal comprising administering an amount of a danazol compound and an amount of a second drug effective to modulate the cytoskeleton. The present invention also relates to pharmaceutical compositions and kits comprising a danazol compound and a second drug. | 2016-06-09 |
| 20160158251 | COMPOSITION FOR PREVENTING OR TREATING MUSCULAR ATROPHY OR PROMOTING MUSCULAR REGENERATION IN SUBJECT COMPRISING SULFONAMIDE COMPOUND AND USE THEREOF - A composition for preventing or treating muscular atrophy or promoting muscular regeneration in a subject including a sulfonamide compound, a pharmaceutically acceptable salt, solvate, or polymorph thereof, or a combination of at least two of the foregoing, and a method of preventing or treating muscular atrophy or promoting muscular regeneration by using the composition. | 2016-06-09 |
| 20160158252 | PHARMACEUTICAL COMPOSITION AND USE OF DIETHYL (2-CYANOETHYL)PHOSPHONATE - The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and diethyl (2-cyanoethyl)phosphonate, or a pharmaceutically acceptable salt thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering diethyl (2-cyanoethyl)phosphonate, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. The present invention is also directed to a method of treating an inflammatory skin disease or disorder, such as dermatitis, psoriasis, acne, or rosacea, by administering to the subject (2-cyanoethyl)phosphonate, or a pharmaceutically acceptable salt or solvate thereof, in an amount effective to reduce or eliminate the symptoms of the inflammatory skin disease or disorder. Topical administration and oral administration are preferred route of administration. | 2016-06-09 |
| 20160158253 | TREATMENT OF PANCREATIC CANCER WITH A COMBINATION OF A HYPOXIA-ACTIVATED PRODRUG AND A TAXANE - Combined administration of a hypoxia-activated prodrug, such as TH-302, a taxane, such as nab-paclitaxel, and a nucleoside analog chemotherapeutic, such as gemcitabine, are efficacious in the treatment of cancer, including pancreatic cancer. | 2016-06-09 |
| 20160158254 | Dosage Forms For Oral Administration of Zoledronic Acid or Related Compounds for Treating Disease - Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome (CRPS). The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form | 2016-06-09 |
| 20160158255 | Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Paget's Disease of Bone - Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailabillty of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form | 2016-06-09 |
| 20160158256 | Dosage Forms for Oral Administration of Zoledronic Acid or Related Compounds for Treating Disease - Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form | 2016-06-09 |
| 20160158257 | DIETARY SUPPLEMENT CONTAINING PHOSPHOLIPID-DHA DERIVED FROM EGGS - Described herein are manufactured dietary supplements that contain a phospholipid extract, folic acid, vitamin D, vitamin B | 2016-06-09 |
| 20160158258 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS - In accordance with some embodiments herein, methods and compositions for prevention and treatment of inflammatory conditions are provided. In some embodiments, compositions comprising NKT-2 activators, for example miltefosine are provided. In some embodiments, the compositions further comprise sulfatide and/or a RAR agonist. In some embodiments, the compositions comprise activators of Type II NKT cells, and/or inhibitors of Type I NKT cells. | 2016-06-09 |
| 20160158259 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES - The present invention relates to compounds and methods for treating retroviral infections and/or Hepatitis B viral infections. Some compounds of the invention are described by Formula I: | 2016-06-09 |
| 20160158260 | Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes - Disclosed are inhibitors of post-proline cleavage enzymes, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. In particular, the inhibitors are improved over those in the prior art by selection of particular classes of side chains in the P1 and/or P2 position of the inhibitor. The inhibitors can have a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease. | 2016-06-09 |
| 20160158261 | Antibiotic Kit and Composition and Uses Thereof - The present invention relates to a therapeutic kit to provide a safe and effective dosage of an antibiotic agent, including an aerosol packaging assembly including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition including: an antibiotic agent; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight, a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition. | 2016-06-09 |
| 20160158262 | METHODS OF TREATING IRRITABLE BOWEL SYNDROME - The present invention provides a method for treating irritable bowel syndrome (IBS) in a subject in need thereof. The treatment can include administering about 550 mg of rifaximin three times per day and about 500 mg of neomycin two times per day for 14 days to the subject to treat the IBS. In certain embodiments, the IBS is constipation predominant IBS (C-IBS). | 2016-06-09 |
| 20160158263 | TREATMENT OF PAPULOPUSTULAR ROSACEA WITH IVERMECTIN - Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments. | 2016-06-09 |
| 20160158264 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions. | 2016-06-09 |
| 20160158265 | ISOLATION OF NOVEL BIOACTIVE COMPOUND OBTAINED FROM OIL PALM BASE MATERIALS - Present invention relates to a composition comprising novel bioactive compound obtained from oil palm based materials and the method of isolating bioactive compound thereof, wherein said compound is an indolacetic acid derivative. The compound is having at least one variation of moiety. | 2016-06-09 |
| 20160158266 | 2' FLUORONUCLEOSIDES - 2′-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: | 2016-06-09 |
| 20160158267 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION - The present invention is directed to selective adenosine A | 2016-06-09 |
| 20160158268 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS - Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT). | 2016-06-09 |
| 20160158269 | Nutraceutical Composition And Methods For Prevention Or Treating Multiple Sclerosis - The present invention embraces nutraceutical compositions containing isolated | 2016-06-09 |
| 20160158270 | BIOMATERIALS COMPRISING HYALURONIC ACID BINDING PEPTIDES AND EXTRACELLULAR MATRIX BINDING PEPTIDES FOR HYALURONIC ACID RETENTION AND TISSUE ENGINEERING APPLICATIONS - The present invention provides novel biomaterial compositions and methods having a technology to improve retention of hyaluronic acid (HA). The biomaterial compositions utilize small HA binding peptides and extracellular matrix binding (ECM) peptides that are tethered to synthetic biocompatible polymers. When tethered to the polymers, the peptide region allows the polymers to bind to HA and to tissues such as cartilage. The novel biomaterial compositions can be used to coat or chemically modify cartilage or tissues with a biologically compatible polymer having HA binding peptides, which allow HA to bind to the surface of the cartilage or tissues. Methods of using same are also provided. | 2016-06-09 |
| 20160158271 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE - The present invention provides an inhibitor of an ADAMTS proteoglycanase for use in treating or preventing cardiac remodeling or for use in treating or preventing heart failure in a subject. In particular, the present invention provides an inhibitor of ADAMTS4 or ADAMTS5 for use in treating or preventing cardiac remodeling or chronic heart failure in a subject with cardiac remodeling or with chronic heart failure, or with a condition that may lead to cardiac remodeling and/or chronic heart failure. Also provided is a method of treating or preventing cardiac remodeling or treating or preventing heart failure which method comprises administering to a subject in need thereof a therapeutically effective amount of an inhibitor of an ADAMTS proteoglycanase. Also provided is the use of an inhibitor of an ADAMTS proteoglycanase in the manufacture of a medicament for treating or preventing cardiac remodeling or treating or preventing heart failure. | 2016-06-09 |
| 20160158272 | OPHTHALMIC COMPOSITIONS COMPRISING POLYETHER SUBSTITUTED POLYMERS - The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300. | 2016-06-09 |
| 20160158273 | BATHWATER AND SOAK ADDITIVE - The present disclosure generally relates to a bathwater additive which renders the bathwater viscous and slippery. | 2016-06-09 |
| 20160158274 | COMPOSITION FOR MUCOUS DISPERSION OR HYDRATION, CONTAINING POLY-r-GLUTAMIC ACID - The present invention relates to a composition for dispersing or hydrating mucus, which comprises poly-gamma-glutamic acid, a biocompatible natural polymer, and more particularly, to a composition for treating mucus hypersecretory disease, which comprises poly-gamma-glutamic acid or poly-gamma-glutamic acid nanogels. The composition according to the present invention is effective in treating mucus-related diseases by effectively dispersing and hydrating mucus which is excessively secreted in vivo and highly sticky. | 2016-06-09 |
| 20160158275 | PHARMACEUTICAL COMPOSITIONS - The present invention relates to crosslinked polyamine particles and/or pharmaceutical compositions comprising, at least in part, crosslinked polyamine particles and aggregates of such particles (including cured aggregates of crosslinked polyamine particles). The compositions may be in the form of tablets comprising, for example, particles larger than 500 μm, and used for treating patients, for example, patients with hyperphosphatemia. | 2016-06-09 |
| 20160158276 | PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES USING SYSTEMS AND METHODS FOR TRANSDERMAL NITRIC OXIDE DELIVERY - The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with acne, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2016-06-09 |
| 20160158277 | IMMUNE MODULATION USING PEPTIDES AND OTHER COMPOSITIONS - The present invention generally relates to compositions and methods for topical or transdermal delivery for immune modulation. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2016-06-09 |
| 20160158278 | BRAIN AND NEURAL TREATMENTS COMPRISING PEPTIDES AND OTHER COMPOSITIONS - The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth, muscle repair, improved muscular and neuromuscular control, and treatments for neuromuscular and neurological disorders, including brain disorders. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptides may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location where muscle growth, muscle repair, or improved muscular and neuromuscular control is desired, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2016-06-09 |
| 20160158279 | SYSTEMS AND METHODS FOR DELIVERY OF PEPTIDES - The present invention generally relates to compositions and methods for topical or transdermal delivery. The compositions can be used in a variety of applications. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. The composition can also be applied to a mucosal surface in some instances. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2016-06-09 |
| 20160158280 | A METHOD FOR ORGAN ARREST, PROTECTION AND PRESERVATION AND REDUCING TISSUE INJURY - The invention relates to compositions and methods for Inducing organ arrest, maintaining arrest and reanimating in a subject that has suffered a life threatening disease or injury; preparing, harvesting, storing organs, tissues and cells; reducing the harmful effects of at least one of anaesthesia, surgery, clinical intervention, and cardiopulmonary bypass on injuring the tissues, organs and cells of a subject; or reducing the harmful effects of surgery or clinical intervention on injuring the organs and brain in the whole body of a subject. The composition comprises (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) citrate. | 2016-06-09 |
| 20160158281 | Surface-Modified Heavy Metal Nanoparticles, Compositions And Uses Thereof - Surface-modified heavy metal nanoparticles, including a heavy metal core and a coating layer, the coating layer having at least one ligand, conjugated to polyethylene glycol, the at least one ligand is selected from N-acetyl cysteine, albumin, cysteine, methionine, glutathione, amino thiols, thio-carboxylic acids, ammonia, amines, diamines or any combination thereof. Compositions including surface-modified heavy metal nanoparticles and uses thereof in treatment and diagnosis of various conditions. | 2016-06-09 |
| 20160158282 | TUNGSTATE TREATMENT OF THE DYSBIOSIS ASSOCIATED WITH GASTROINTESTINAL INFLAMMATION - The present invention provides compositions of therapeutic agents and methods of use for reducing and/or treating gastrointestinal inflammation. In particular aspects, the tungstate salts described herein and pharmaceutical compositions thereof inhibit the activity of one or a plurality of anaerobic respiratory enzymes in facultative anaerobic bacteria such as, for example, Enterobacteriaceae, that can exacerbate inflammation. In particular embodiments, the present invention provides compositions of therapeutic agents for treating gastrointestinal inflammation, as well as methods for treating or preventing gut microbial imbalance due to an increase in the abundance of intestinal Enterobacteriaceae. | 2016-06-09 |
| 20160158283 | COMPOSITIONS AND METHODS FOR DENTAL MINERALIZATION - The present invention relates to compositions for mineralizing a dental surface, in particular tooth enamel. Methods of mineralizing hypomineralized lesions (including subsurface lesions) in the tooth enamel caused by dental caries, dental corrosion and fluorosis are also provided. In particular, the invention relates to a method of mineralizing a dental surface or subsurface comprising contacting the dental surface or subsurface with a compound that is capable of increasing or maintaining the pH of a solution and a mineralizing agent. | 2016-06-09 |
| 20160158284 | LASER ASSISTED WOUND HEALING PROTOCOL AND SYSTEM - A method of treating gum disease while healing the wound in the periodontium using a soft tissue diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400 nm-700 nm) at a laser power of 0.001 to 1.2 watts, used with intermittent stops to control tissue temperature and biostimulate the periodontium to regenerate and heal its wound when used with substrates, the method comprising: placing the tip of the laser inside the sulcus; penetrating the entire sulcus by moving the laser light circumferentially around the tooth vertically and horizontally throughout the sulcus with intermittent stops to control tissue temperature and placing substrates in the sulcus prior to blood clot formation; followed by RF treatment of the sulcus by placing the RF headpiece tips perpendicular to the sulcus to receive RF current which further penetrates the wound site. | 2016-06-09 |
| 20160158285 | HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS - The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment. | 2016-06-09 |
| 20160158286 | Cell Preparations For Extemporaneous Use, Useful for Healing and Rejuvenation In Vivo - The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell combinasons preparations for use in tissue regeneration and bone regeneration and pain reduction. | 2016-06-09 |
| 20160158287 | NEW PROPHYLACTIC USE FOR PREVENTION OF INFECTIONS - The present invention concerns the field of nutritional compositions and concerns a nutritional composition, especially an infant formula containing whey protein/milk protein concentrate solids rich in phospholipids, rich in MFGM for use in the prophylaxis and prevention of infectious morbidity, especially otitis. At the same time the use of antipyretics has diminished. | 2016-06-09 |
| 20160158288 | METHODS AND COMPOSITIONS FOR EXPANDING LONG-TERM HEMATOPOIETIC STEM CELL POPULATIONS - The invention generally features compositions and methods for expanding long term hematopoietic stem cells (HSCs) in a population of cells. In particular, the invention relates to a method of expanding long term HSCs by culturing an initial population of HSCs with macrophages that promote self-renewal of long term HSCs. The expanded cell population provides a source of cells for therapeutic treatments utilizing HSC transplantation. | 2016-06-09 |
| 20160158289 | MATERIALS AND METHODS FOR USING ADIPOSE STEM CELLS TO TREAT LUNG INJURY AND DISEASE - The present disclosure provides methods for treating patients with acute or chronic lung disease or injury to the lungs including injury caused by exposure to cigarette smoke other irritants or another cause of pulmonary distress. Typical conditions that can be treated include conditions that cause inflammation in the lung or the death of lung endothelial cells. Treatment of other conditions such as compromised bone marrow function and cachexia can also be treated by the inventive methods disclosed herein. These methods including contacting Adipose Stem Cells (ASC) or media conditioned by contact with ASC (ASC-CM) or various factors secreted by the same including the media or components of the media with lung tissue and cells. In some instances the ASC used is harvested from the patient's own adipose tissue while in other instances the source is an exogenous donor. | 2016-06-09 |
| 20160158290 | METHOD FOR TREATING CANCER - The present invention relates to a method for preventing or treating cancer in an individual comprising administering the individual with a prophylactically or therapeutically effective quantity of a gingival fibroblast-derived product. | 2016-06-09 |
| 20160158291 | PROCESSES FOR PRODUCING STABLE EXOSOME FORMULATIONS - The invention encompasses methods for generating stable exosome formulations and encompasses stable exosome formulations. The exosome formulations encompass stable liquid exosome formulations and stable lyophilized exosome formulations. In some embodiments, the exosome formulations can be generated by ultrafiltration and diafiltration. The exosome formulations can be suitable for administration to a human. | 2016-06-09 |
| 20160158292 | METHOD AND APPARATUS FOR RECOVERY OF UMBILICAL CORD TISSUE DERIVED REGENERATIVE CELLS AND USES THEREOF - Methods for the extraction and processing of umbilical stem cells for therapeutic and diagnostic purposes are disclosed. The methods provide high regenerative cell numbers and high cell viability. Further, the methods do not require culturing the cells in serum or growth factors. | 2016-06-09 |
| 20160158293 | Treatment of Ocular Conditions Using Progenitor Cells - Methods and compositions for treating ophthalmic disease, promoting development of functional neuronal synapses and improving neuronal outgrowth using progenitor cells, such as postpartum-derived cells, and conditioned media from the cells, are disclosed. Trophic factors and other agents secreted by the cells that promote synapse formation and neuronal growth are also disclosed. | 2016-06-09 |
| 20160158294 | Methods of Populating a Gastrointestinal Tract - Methods and compositions for populating the gastrointestinal tract of a subject are described. Methods include administering to a subject a therapeutic composition comprising a purified population of spore-forming bacteria produced by providing a fecal material and subjecting the material to a treatment step resulting in purification of spore forming bacteria. Methods include administering an amount effective to engraft and/or augment in the gastrointestinal tract in order to treat or prevent a dysbiosis in the mammalian subject. | 2016-06-09 |
| 20160158295 | Compositions and Methods - Provided are defined bacterial compositions for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for populating the gastrointestinal tract of a subject. Provided also are bacterial formulations for oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition. | 2016-06-09 |
| 20160158296 | LACTOCOCCUS LACTIS STRAINS FOR PRODUCING BIOACTIVE PEPTIDES HAVING ANTI-HYPERTENSIVE AND CHOLESTEROL-LOWERING EFFECTS | 2016-06-09 |
| 20160158297 | EXTRUDED NON-REPLICATING PROBIOTIC MICRO-ORGANISMS AND THEIR HEALTH BENEFITS - Compositions include probiotic microorganisms that were rendered non-replicating by extrusion. Such compositions may be used to treat or prevent disorders that are related to a compromised immune system. | 2016-06-09 |
| 20160158298 | MEDICAL CANNABIS LOZENGES AND COMPOSITIONS THEREOF - A method for optimizing the therapeutic effects provided by CBD on the one hand, and the psychoactive effects provided by THC on the other hand, in a sublingual medicament, the method includes the steps of obtaining a concentrated extract of | 2016-06-09 |
| 20160158299 | Cannabidiol (CBD) Enriched Alcohol - A cannabinoid enriched alcohol composition for human consumption and method of manufacture for the composition are disclosed. The composition includes by weight about ninety-nine point nine-two percent (99.92%) ethanol in a liquid state and by weight about zero point zero eight percent (0.08%) cannabinoid in a liquid state. The composition is made by providing the ethanol in a liquid state and by providing the cannabinoid in the form of a cannabidiol oil in a liquid state, further a next step of combining the ethanol and the cannabidiol oil forming an initial mixture and agitating the initial mixture until the cannabidiol oil and the ethanol are in a substantially emulsified state with one another in a liquid state forming a completed mixture. | 2016-06-09 |
| 20160158300 | USE OF PLANT EXTRACTS AGAINST HERPES SIMPLEX VIRUS - The present invention provides a method of using a plant extract or active fraction thereof for inhibiting an herpes simplex virus (HSV) infection, wherein the plant is a: | 2016-06-09 |
| 20160158301 | Association Between Neopterin Concentration and Neurovascular Charges in Type-2 Diabetes Patients - Effect of an Ayurvedic Formulation Mainly Containing Berberis Aristata - Provided herein are plant based formulations for the prevention and management of diabetic vascular complication The formulation include hydro-alcoholic extract of | 2016-06-09 |
| 20160158302 | Regulation of Brain Biogenic Amines Associated with Depression by a Formulation from Botanical Source - Provided herein are anti depressant and anxiolytic herbal formulations including: 225-450 mg of | 2016-06-09 |
| 20160158303 | METHOD OF EXTRACTING FLAVONOIDS AND/OR POLYPHENOLS FROM DRIED AND POWDERED CITRUS PEELS, COMPOSITIONS THEREFROM, AND METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH CHRONIC INFLAMMATION - Improved processes for extracting polyphenols and/or flavonoids from citrus peels are provided that comprise 1) heating a ground peel to form a pre-treated, ground peel; and 2) extracting the compounds of interest from the pre-treated, ground peel using a basic solution of pH greater than 7 and less than 12. Such processes serve to increase the efficiency of extraction of the polyphenols and/or flavonoids. In preferred embodiments, the flavonoids extracted include hesperidin and narirutin. These extracts are useful in the preparation of anti-inflammatory medicaments for the treatment of chronic inflammatory disorders such as inflammatory bowel disease, Crohn's disease, irritable bowel syndrome (IBS), and multiple sclerosis. | 2016-06-09 |
| 20160158304 | Composition, and Method of Using the Composition, Effective for Minimizing the Harmful Effects Associated with Individuals Suffering from Alcohol Intoxication - The present invention relates to a composition, and methods of using the composition, for minimizing the harmful effects associated with alcohol consumption. The composition includes a plurality of ingredients, which when combined, have the unexpected effect of increasing one or more metabolic pathways in the individual. As the metabolic rate is increased, alcohol is burned off, or utilized as energy source, and occurs at a considerably much faster rate than under normal physiological means. It is believed that the composition may have an effect on the brain causing it to increase metabolic rates. By administering the composition to an inebriated individual, the rate at which a person sobers up, occurs at a faster rate than would occur under normal physiological time frames. | 2016-06-09 |
| 20160158305 | ADDITIVES AND SUPPLEMENTS - Disclosed are ingestible additives and ingestible supplements that are capable of promoting liver function, promoting liver health, or reducing alcoholic hepatopathy in a subject. The ingestible additive or supplement can include at least one essential amino acid, at least non-essential amino acid, at least one antioxidant, at least one lipotropic compound, at least one water-soluble vitamin, or at least one plant or extract thereof. | 2016-06-09 |
| 20160158306 | HERBAL COMPOSITION FOR INCREASING FERTILITY IN MEN AND A METHOD OF SYNTHESIZING THE SAME - The embodiments of the present invention provide herbal syrup comprising | 2016-06-09 |
| 20160158307 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis - The present invention provides a family of novel cytotoxic pentapeptides, which show potent antitumor activities against several cancer lines. The antibody-drug conjugates prepared from those pentapeptides can efficiently kill cancer cells. | 2016-06-09 |
| 20160158308 | TREATMENT OF MULTIPLE EVOLVING BACTERIAL RESISTANCE DISEASES WITH LIPOSOMALLY FORMULATED GLUTATHIONE - The invention proposes routine treatment of patients, particularly those admitted to an ICU, with Vitamin D and liposomal glutathione for prophylaxis and treatment against Group B | 2016-06-09 |
| 20160158309 | EXERCISE FUNCTION ENHANCER - The inventors of the present invention have discovered that glutathione inhibits reduction in muscle pH, and activates PGC-1α to increase production of mitochondrial DNA. The present invention has been completed based on these findings. | 2016-06-09 |
| 20160158310 | PEPTIDE SYSTEMS AND METHODS FOR METABOLIC CONDITIONS - The present invention generally relates to compositions and methods for topical or transdermal delivery, and treatment of metabolic conditions. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2016-06-09 |
| 20160158311 | POLYMER CONJUGATES OF PROTEGRIN PEPTIDES - The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer. | 2016-06-09 |
| 20160158312 | POLYPEPTIDES AND IMMUNIZING COMPOSITIONS CONTAINING GRAM POSITIVE POLYPEPTIDES AND METHODS OF USE - The present invention provides isolated polypeptides isolatable from a | 2016-06-09 |
| 20160158313 | CLATHRIN THERAPEUTIC FOR INFECTIOUS DISEASES - The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating an infectious disease, condition, or disorder in vivo or in vitro. | 2016-06-09 |
| 20160158314 | GLYCOSYLATED PROTEIN OF AN EXTRA-CELLULAR MATRIX FOR USE IN A METHOD OF TREATING AN ISCHEMIC HEART OF A HUMAN OR ANIMAL SUBJECT IN NEED THEREOF - The present invention relates to a glycosylated protein of an extracellular matrix, preferably of a mammalian extra-cellular matrix for use in a method of treating an ischemic heart of a human or animal subject in need thereof, a pharmaceutical composition comprising said glycosylated protein and a method for the in vitro production of differentiated cardiomyocytes. | 2016-06-09 |
| 20160158315 | RECOMBINANT HUMAN CC10 AND COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF NASAL RHINITIS - The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis. More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10 and intranasal route of administration, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans. | 2016-06-09 |
| 20160158316 | DRG11-RESPONSIVE (DRAGON) GENE FAMILY - This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein and nucleic acid sequences of human, murine, zebrafish, and | 2016-06-09 |
| 20160158317 | Antimicrobial Peptide Variants and Polynucleotides Encoding Same - The present invention relates to variants of a parent antimicrobial peptide. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 2016-06-09 |
